Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If/when the earnings for ANTH comes out on May 8th and they're decent, there should definitely be a move upward, IMO of course. I'm hoping for good news and a even better run north.
This information on ANTH was pulled from Zack's and they've listed it as a "HOLD". This wasn't written by me, just posted to the ANTH board for all to know.
ANTH is a "Buy" rating based on its strong fundamental and real valuation! Easy double within just a few weeks from current ridiculous low price levels! The stock worth $0.6 per share at least...
"Zack's rating" is purely garbage/junk and it is 100% against any stock's real moving trend! Thus it is 100% useless and meaningless!
Today Over 220K shares bid at the New bottom $0.31! The Level2 of ANTH is ready to run!
ANTH is Hyper Undervalued now! It is also Hyper Oversold since near $3 (just a month ago)!
Zacks Investment Research, Inc. downgrades ANTHERA PHARMACEUTICALS INC from BUY to HOLD.
BY Investars Analyst Actions - private — 7:22 AM ET 04/26/2018
On April 26, 2018 Zacks Investment Research, Inc. downgraded ANTHERA PHARMACEUTICALS INC (ANTH) from BUY to HOLD.
The Cash Value alone is over $0.68 per share and easy double from here! ANTH worth at least $0.60 a share in a Buy-Out or R-M deal...
Thanks for the heads up :)
ANTH is Extremely Undervalued now! Great Buy-Out candidate! It has been Hyper Oversold since April 12's high $0.367! Huge price gap between $1.20 and $0.57 will be filled up very soon! Therefore easy double from the current basement price levels!
April 23rd 2018 - The Best Stock Investment For 2018 - Mymetics Corp. (MYMX)
" Mymetics Corp (MYMX) and Sanofi are currently working on a redesigned study to compare the immunogenicity of Mymetics’ influenza virosomes with that of Sanofi Pasteur’s egg-based split vaccine."
https://askwarrenbuffet.blogspot.com/2018/02/the-best-investment-for-2018-is.html
Surprisingly, they didn't mention MACIVIVA!
Mymetics is leading a consortium of 4 other companies.
MACIVIVA = Game Changer = Disrupting the vaccine industry worldwide!
MACIVIVA latest Progress' Reporting Period Posted: https://cordis.europa.eu/result/rcn/194900_en.html
Copy of latest MACIVIVA presentation (downloadable): https://www.mymetics.com/media-center/world-vaccine-congress-10-12-october-2017-barcelona/
Would have been better in the hands of the Americans pps wise since 2012?
Dr. Christopher Henney, currently Chairman of BOD at Anthera Pharmaceuticals(ANTH) and Cascadian Therapeutics(CSCA)(formerly Oncothyreon)-recently acquired by Seattle Genetics, and Director at Cyclacel Therapeutics(CYCC); and former Dendreon co-founder & CEO was once on board with this unknown microcap as Chairman of BOD but seems like had a disagreement with the largest shareholder that led him and his Dendreon protege to leave in less than a year.
https://www.xconomy.com/san-francisco/2012/04/11/mymetics-ropes-in-dendreon-kpcb-vets-to-restart-vaccine-developer/
Nice low entry! ANTH has already built up a rocket-solid forever bottom at $0.3001 and it was already closed above its 20-Day MAL. The technical resistance (20-Day MAL and 200-Day MAL) are all above $1.1 v.s. the psychological resistance is the most recent high $0.57. Huge short-term gain potential here with patience and some good news from the company...
Surprising Stocks – Anthera Pharmaceuticals, Inc., NASDAQ: ANTH)
By DNN TEAM - April 20, 2018
Anthera Pharmaceuticals, Inc.
The Healthcare stock (Anthera Pharmaceuticals, Inc.) showed a change of 0.38 percent from opening and finally turned off its business at $0.34 by scoring 2.99 percent on 19-04-2018. Anthera Pharmaceuticals, Inc., belongs to Healthcare sector and Biotechnology industry.
Historical Performance Review: To understand the smudge picture investors will must to look a little deeper. The Anthera Pharmaceuticals, Inc. has shown a five days performance of -3.21% and thirty days performance stands at 3.62%. The stock has shown a ninety days performance of -73.57% and a six months performance stands at -77.86%.
Market Capitalization/Outstanding Shares/Intraday Volume: The company’s Market capitalization is $7.99M with the total Outstanding Shares of 23.43M. Market capitalization refers to the entire dollar market cost of a company’s outstanding shares. Referred to as “market cap,” it is determined by doubling a company’s shares outstanding by the current market price of one share. Outstanding shares refer to a company’s stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s officers and insiders.
The Anthera Pharmaceuticals, Inc. exchanged hands with 1392735 shares compared to its average daily volume of 3.03M shares. Total volume is the number of shares or deals that point towards the overall activity of a security or market for a given period. Volume is an important indicator in technical analysis as it is used to measure the relative worth of a market move. If the markets make a firm price movement, then the strength of that movement depends on the volume for that period. The higher the volume during the price move, the more significant the progress.
Institutional Ownership/ Insider Ownership: Anthera Pharmaceuticals, Inc. institutional ownership is held at 26.5% while insider ownership was 1.78%. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. Institutions purchase large blocks of a company’s outstanding shares and can exert considerable influence upon its management.
P/S, P/E, P/C and P/B/ SMA50, SMA 200: The price-to-sales is a valuation ratio that relates a company’s stock price to its revenues. The price-to-sales ratio is a symbol of the value placed on each dollar of a company’s sales or taxes. As of now, ANTH has a P/S, P/E and P/B values of 0, 0 and 0 respectively. P/E and P/B ratios both are used on a regular basis by the investor to measure the value of the company and to get the right amount of the share.
Its P/Cash valued at 3.63. The price-to-cash-flow ratio is a stock valuation indicator that measures the value of a stock’s price to its cash flow per share
The stock has observed its SMA50 which is now -70.47%. In looking the SMA 200, we see that the stock has seen an -76.75%.The Company’s net profit margin for the 12-months at 0%. Comparatively, the company has a Gross margin 0%.
Profitability Ratios (ROE, ROA, ROI): Looking into the profitability ratios of ANTH stock, an investor will find its ROE, ROA, ROI standing at 0%, -234.4% and 0%, respectively. Return on assets (ROA) is a financial ratio that shows the percentage of profit a company earns about its overall resources. A performance measure used to estimate the efficiency of an investment or to compare the ability of some different investments. ROI measures the amount of return on an investment relative to the investment’s cost.
Earnings per Share Details of Anthera Pharmaceuticals, Inc.: The EPS of ANTH is strolling at -3.31, measuring its EPS growth this year at 77.8%. As a result, the company has Earnings per Share (EPS) growth of 18.7% for the coming year. Given the importance of identifying companies that will ensure earnings per share at a high rate, we later obsession to umpire how to determine which companies will achieve high amassing standards. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years. We can’t have enough maintenance the once will always reflect the difficult, but logically stocks that have grown earnings per allowance sharply in the after are an excellent bet to continue to take effect as a result.
Target Price/Analysts Mean Suggestion: Mostly, a price target is an individual analyst’s expectation on the future price of a security, usually a stock. There may be many price targets for only protection. Analyst’s mean target cost for the company is $6.5 while analysts mean suggestion is 2.
Beta/Volatility: A beta factor is used to measure the volatility of the stock. A Beta component of the stock stands at 2.77. Beta element is utilized to gauge the unpredictability of the stock. The stock remained 5.66% volatile for the week and 9.86% for the month.
Source: https://www.dailynysenews.com/surprising-stocks-anthera-pharmaceuticals-inc-nasdaq-anth-valvoline-inc-nyse-vvv/
Attention to the volume of today ...
I have my jeopardy music playing softly in the background waiting for $ANTH to make some type of upward move....
Total 1,472,200 Shorted shares which will generate huge Shorting-Squeezing effect when ANTH breaks up $0.388! Those stupid shorters will Chase To Cover their large shorting positions which will easily drive ANTH back to $0.6xxx or higher price levels!
Keep in mind, there is an huge price Gap between $0.57 and $1.20 (see the chart below) which will be filled up sooner or later...
premarket Last: $ 0.38 ? 0.02 (6.73%)
Great info there, but hindsight is always 20/20 so you're not telling anyone anything they don't know at the present time
No. It only bounced 42.5% from $0.40 to $0.57! Now all those $0.50 ~ $0.57 buyers are in the Deep Huge losses...
$0.57 was the Top ceiling price since the Giant crash from near $3!
Yes, chart was due for small bounce. IMO rs is only one option for this company.
You're possibly correct. Although the charts were correct in a small bounce, I had to bow out with a small profit.
GLT All
No catalyst at all. Dead money.
Started a position here based merely on charts. Is there any catalyst, news wise, expected any time soon?
I like the looks of MACD crossing soon.
Thanks in advance.
can this company sustain itself ? and is the bottom in?
tic toc tic toc looking to explode nice reversal in got more
hold on tight ladies and gents, we go parabolic.
Dr. Christopher Henney, currently Anthera Pharmaceuticals (ANTH) & Cascadian Therapeutics(CSCA)formerly Oncothyreon, Chairman of the Board; Director at Cyclacel Pharmaceuticals and former Dendreon co-founder & CEO was once on board with this unknown microcap as Chairman of BOD but seems like had a disagreement with the largest shareholder that led him and his Dendreon protege to leave in less than a year.
https://www.xconomy.com/san-francisco/2012/04/11/mymetics-ropes-in-dendreon-kpcb-vets-to-restart-vaccine-developer/
this is the time dudes , going up
Looks very good from here , just got more down here
starter position here @ 0,355 , good luck dudes!!!!!
0,35,,,near 0,3 could be a good trade
its equal than aker,,going down the first candle after the crash,,,next week its the key, good luck!!
I'm down more than 20%, not looking good.
going down 0,4, lets see next week what hapens,,, maybe we see 0,3
Could but I doubt that. It bottomed at .40 for its first support. Time will tell.
or this can see red to low 30's before rebound then selling and trading sideways until PR helps swing it. They have been taken over as a stock selling firm that happens to have some drugs that may get approved down the line... or not get approved as most recently. IF it dips more I might get in for the next pump. I think the timing of the pump might be different than how it went down last summer.
Alright, now that we have had a whole trading session, trading side ways, the whales will come in and sweep this thing to just past $1. The time to load at these prices is drawing to and end. Just FYI in my opinion.
i hope you are right. i got a ton today at 0.50
I'll take 0.90 :)
I've been through this a ton of times, especially with these stocks and same scenario. It will run till it reaches just above $1, a psychological resistance. Then dip to 90, then 80, then settle at 75 for a bit, maybe bounce to 80, head back down to 60, 50, and rest back at mid 40's till some good news. I will be selling at high 90's to get a good execution, nearly doubling my money as I am in at 47,49,52, and 54. Then I'll move on and keep it on my radar. Nothing complicated.
Got in big time. .49. This will go back to. 1.00+ imo.
Followers
|
57
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2495
|
Created
|
03/01/10
|
Type
|
Free
|
Moderators |
Anthera Pharmaceuticals Inc.
Nasdaq: ANTH
Contact Info
25801 Industrial Blvd, Suite B • Hayward, CA 94545
Press Contact: pr@anthera.com
Business Development: bd@anthera.com
Vendors: ap@anthera.com
Website: www.anthera.com
J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors Paul F. Truex appointed as Executive Chairman of the Board Dr. Christopher Henney stepped down as Chairman ...
http://finance.yahoo.com/q?s=ANTH
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation,
including cardiovascular and autoimmune diseases. We currently have a Phase 2 clinical program, blisibimod.It was just recently approved by FDA to move into
PHASE 3
Blisibimod targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.
It has taken the lupus research community over 50 years to produce a new therapy. Although it is now a year old, Benlysta (belimumab),
now marketed by GlaxoSmithKline and Human Genome Sciences, is the first human monoclonal antibody for the treatment
of lupus.
Benlysta had a slow take-off grossing $59.2 million in sales in the last three quarters of 2011, but it was approved in numerous
countries by year's end. Estimated sales for Benlysta in 2012 are said to be about $230 million, with first annual profits likely by 2015.
The surprisingly slow uptake of Benlysta allows for blisibimod to develop into a promising drug as
it currently has more desirable features than that of Benlysta.
Blisibimod has a dosing regimen of one injection weekly, compared to that of Benlysta which requires a
series of dosing before the maintenance dose begins. Also, Benlysta has limitations on usage pertaining to
specific patient populations and has not been studied in combination with other biologics.
These attributes of blisibimod including a different mechanism of action, will set it apart from
Benlysta, Global Data concludes.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |